Vallée Alexandre, Vasse Marc, Mazaux Laurence, Bonan Brigitte, Amiel Carline, Zia-Chahabi Sara, Chan-Hew-Wai Aurélie, Farfour Eric, Camps Eve, Touche Pauline, Barret Flavie, Parquin François, Zucman David, Fourn Erwan
Department of Clinical Research and Innovation, Foch Hospital, 92150 Suresnes, France.
Biology Department, Foch Hospital, 92150 Suresnes, France.
J Clin Med. 2021 Aug 25;10(17):3817. doi: 10.3390/jcm10173817.
There is a small amount of immunological data on COVID-19 heterologous vaccination schedules in humans. We assessed the immunogenicity of BNT162b2 (Pfizer/BioNTech) administered as a second dose in healthcare workers primed with ChAdOx1-S (Vaxzevria, AstraZeneca).
197 healthcare workers were included in a monocentric observational study in Foch hospital, France, between June and July 2021. The main outcome was the immunogenicity measured by serum SARS-CoV-2 IgG antibodies.
130 participants received the ChAdOx1-S/BNT vaccine and 67 received the BNT/BNT vaccine. The geometric mean of IgG antibodies was significantly higher in the BNT/BNT vaccine group compared to the ChAdOx1-S/BNT vaccine group, namely 10,734.9, 95% CI (9141.1-12,589.3) vs. 7268.6, 95% CI (6501.3-8128.3), respectively ( < 0.001). However, after adjustment for time duration between the prime and second vaccinations, no significant difference was observed ( = 0.181). A negative correlation between antibody levels and time duration between second dose and serology test was observed for the BNT/BNT vaccine ( < 0.001), which remained significant after adjustment for all covariates ( < 0.001), but not for the ChAdOx1-S/BNT vaccine ( = 0.467).
Heterologous and homologous schedules of ChAdOx1-S and BNT vaccines present robust immune responses after the second vaccination. The results observed were equivalent after adjustment for covariates and emphasize the importance of flexibility in deploying mRNA and viral vectored vaccines. Nevertheless, applying the ChAdOx1-S schedule vaccination for the heterologous second dose of BNT was associated with decreased IgG antibody levels compared to the homologous BNT/BNT vaccination.
关于新冠病毒（COVID-19）异源疫苗接种方案在人体中的免疫学数据较少。我们评估了在接种ChAdOx1-S（阿斯利康公司的Vaxzevria）进行初始免疫的医护人员中，将BNT162b2（辉瑞/ BioNTech公司）作为第二剂接种时的免疫原性。
2021年6月至7月期间，197名医护人员纳入法国福煦医院的一项单中心观察性研究。主要观察指标是通过血清严重急性呼吸综合征冠状病毒2（SARS-CoV-2）IgG抗体测量的免疫原性。
130名参与者接受了ChAdOx1-S/BNT疫苗接种，67名接受了BNT/BNT疫苗接种。与ChAdOx1-S/BNT疫苗组相比，BNT/BNT疫苗组IgG抗体的几何平均值显著更高，分别为10,734.9，95%置信区间（CI）（9141.1 - 12,589.3）和7268.6，95% CI（6501.3 - 8128.3）（<0.001）。然而，在对初始免疫和第二剂接种之间的时间间隔进行调整后，未观察到显著差异（=0.181）。对于BNT/BNT疫苗，观察到抗体水平与第二剂接种和血清学检测之间的时间间隔呈负相关（<0.001），在对所有协变量进行调整后仍具有显著性（<0.001），但对于ChAdOx1-S/BNT疫苗则无此相关性（=0.467）。
ChAdOx1-S和BNT疫苗的异源和同源接种方案在第二剂接种后均呈现出较强的免疫反应。在对协变量进行调整后，观察到的结果相当，这强调了在部署信使核糖核酸（mRNA）疫苗和病毒载体疫苗时灵活性的重要性。然而，与同源的BNT/BNT接种相比，采用ChAdOx1-S接种方案进行BNT的异源第二剂接种与IgG抗体水平降低相关。
